Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation provides readers with an authoritative, comprehensive and targeted treatment guide. The first section reviews the essential knowledge and methods of clinical neuroscience and neuropsychopharmacological techniques as they apply to novel treatment discovery for depression. This is followed by detailed chapters on ketamine, esketamine, other glutamate modulators in development, GABA modulators, neuropeptides, anti-inflammatory agents, and other classes of novel therapeutics under study for TRD and related mood disorders.
The last section consists of a set of chapters of special interest that includes current and future research directions, development of psilocybin-based interventions and other psychedelic compounds currently under study for TRD and advances in biomarker-guided and personalized treatment. Edited by world renowned experts in the field, this book is the ultimate resource for researchers and clinicians.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. List of contributors - p. ix 7. About the editors - p. xi 8. Foreword - p. xiii 9. Preface - p. xv 10. Chapter 1. Treatment-resistant depression: epidemiology and clinical presentation - p. 1 11. Chapter 2. Molecular neuropharmacology of treatment-resistant depression - p. 15 12. Chapter 3. Neurobiology and neuroimaging of treatment resistant depression - p. 39 13. Chapter 4. Pharmacotherapy of treatment-resistant depression: overview and look ahead - p. 59 14. Chapter 5. Lithium, dopamine modulators, and other augmentation strategies for treatment-resistant depression - p. 83 15. Chapter 6. Ketamine and esketamine for treatment-resistant depression - p. 103 16. Chapter 7. Impact of inflammation on treatment resistance in depression: mechanisms and translational opportunities - p. 123 17. Chapter 8. Novel pharmacotherapies for treatment-resistant depression: a focus on glutamate and gamma-aminobutyric acid modulators - p. 145 18. Chapter 9. Electroconvulsive therapy for treatment-resistant depression - p. 169 19. Chapter 10. Transcranial magnetic stimulation for treatment-resistant depression - p. 207 20. Chapter 11. Vagal nerve stimulation for treatment-resistant depression - p. 245 21. Chapter 12. Deep brain stimulation for treatment-resistant depression - p. 271 22. Chapter 13. Psilocybin and other psychedelic agents in development for treatment-resistant depression - p. 289 23. Chapter 14. Neuroimaging biomarkers in treatment selection for treatment-resistant depression - p. 329 24. Chapter 15. The role of genetics in treatment-resistant depression - p. 361 25. Index - p. 377
Therapies for Treatment-Resistant Depression: Neuropharmacology and Neurostimulation provides readers with an authoritative, comprehensive and targeted treatment guide. The first section reviews the essential knowledge and methods of clinical neuroscience and neuropsychopharmacological techniques as they apply to novel treatment discovery for depression. This is followed by detailed chapters on ketamine, esketamine, other glutamate modulators in development, GABA modulators, neuropeptides, anti-inflammatory agents, and other classes of novel therapeutics under study for TRD and related mood disorders.
The last section consists of a set of chapters of special interest that includes current and future research directions, development of psilocybin-based interventions and other psychedelic compounds currently under study for TRD and advances in biomarker-guided and personalized treatment. Edited by world renowned experts in the field, this book is the ultimate resource for researchers and clinicians.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iv 6. List of contributors - p. ix 7. About the editors - p. xi 8. Foreword - p. xiii 9. Preface - p. xv 10. Chapter 1. Treatment-resistant depression: epidemiology and clinical presentation - p. 1 11. Chapter 2. Molecular neuropharmacology of treatment-resistant depression - p. 15 12. Chapter 3. Neurobiology and neuroimaging of treatment resistant depression - p. 39 13. Chapter 4. Pharmacotherapy of treatment-resistant depression: overview and look ahead - p. 59 14. Chapter 5. Lithium, dopamine modulators, and other augmentation strategies for treatment-resistant depression - p. 83 15. Chapter 6. Ketamine and esketamine for treatment-resistant depression - p. 103 16. Chapter 7. Impact of inflammation on treatment resistance in depression: mechanisms and translational opportunities - p. 123 17. Chapter 8. Novel pharmacotherapies for treatment-resistant depression: a focus on glutamate and gamma-aminobutyric acid modulators - p. 145 18. Chapter 9. Electroconvulsive therapy for treatment-resistant depression - p. 169 19. Chapter 10. Transcranial magnetic stimulation for treatment-resistant depression - p. 207 20. Chapter 11. Vagal nerve stimulation for treatment-resistant depression - p. 245 21. Chapter 12. Deep brain stimulation for treatment-resistant depression - p. 271 22. Chapter 13. Psilocybin and other psychedelic agents in development for treatment-resistant depression - p. 289 23. Chapter 14. Neuroimaging biomarkers in treatment selection for treatment-resistant depression - p. 329 24. Chapter 15. The role of genetics in treatment-resistant depression - p. 361 25. Index - p. 377
